We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01181856
Recruitment Status : Completed
First Posted : August 13, 2010
Last Update Posted : March 28, 2011
Information provided by:
University of Oxford

Brief Summary:
This is a phase I study that will compare the safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route in healthy adult individuals who have been previously vaccinated with Bacillus Calmette-Guerin (BCG).

Condition or disease Intervention/treatment Phase
Tuberculosis Biological: MVA 85A Phase 1

Detailed Description:

We postulate that the intramuscular route is not inferior to the intradermal route of administration of MVA85A in BCG vaccinated adults when evaluated for safety and immunogenicity.

If MVA85A can be given safely by intramuscular route and it is at least equally immunogenic and efficacious in a prime-boost strategy, then it would probably be the preferred route in subsequent phase II and III trials. There are several reasons for this:

  • Reduced pain associated with injection.
  • Reduced local reaction at the injection site.
  • More straightforward procedure; less technically demanding; less time consuming.
  • Easier production and storage of vaccine.
  • Larger volume of vaccine can be given.

Trials of MVA85A to date have established 1 x 10^8 pfu as the optimal dose for intradermal injection in adults. We therefore intend to administer this same dose intramuscularly in order to directly compare the two routes for both safety and immunogenicity. These results will guide future trials in which the intramuscular route, if safe, could be further evaluated at either higher or lower dose depending on immunogenicity at 1 x 10^8 pfu dosage.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity of Candidate Tuberculosis (TB) Vaccine MVA85A Administered by the Intramuscular Route and the Intradermal Route: a Phase I Randomised Active Controlled Trial
Study Start Date : January 2010
Actual Primary Completion Date : January 2011
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group A
Intramuscular immunisation
Biological: MVA 85A
Single injection of 1 x 108 pfu MVA85A

Experimental: Group B
Intradermal immunisation
Biological: MVA 85A
Single injection of 1 x 108 pfu MVA85A

Primary Outcome Measures :
  1. Safety [ Time Frame: 6 months following vaccination ]
    Safety data in both groups, as assessed by the frequency, incidence, and nature of adverse events (AEs) and serious adverse events (SAEs) during the study. Safety is measured throughout the 6 months follow up period, but specifically on the following days: 2, 7, 14, 28, 56, 84 and 168 and. Blood for safety testing is taken at Days 7 and 28.

Secondary Outcome Measures :
  1. Immunogenicity [ Time Frame: 6 months following vaccination ]
    Immunogenicity data in both groups. This will be obtained from exploratory immunological laboratory investigations on blood samples taken at screening, and throughout follow up. Immunogenicity is measured throughout the 6 months follow up period, but specifically on the following days: 2, 7, 14, 28, 56, 84 and 168.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy adult aged 18 - 55 years (both male and female)
  2. Resident in or near Oxford for the duration of the study period
  3. Confirmation of prior vaccination with BCG not less than 3 months prior to projected study vaccination date (by visible BCG scar on examination or written documentation)
  4. Normal medical history and physical examination
  5. Willingness to allow the Investigators to discuss the individual's medical history with their GP
  6. Willingness to use continuous effective barrier contraception for three months after receiving the vaccination (males and females)
  7. Willingness to use effective contraception for the duration of the study period (females only)
  8. Agreement to refrain from blood donation during the course of the study
  9. Give written informed consent
  10. Agreement to allow the Investigator to register volunteer details with a confidential database to prevent concurrent entry into clinical trials
  11. Able and willing (in the Investigator's opinion) to comply with all the study requirements

Exclusion Criteria:

  1. Clinical, radiological, or laboratory evidence of current active TB infection
  2. Laboratory evidence at screening of latent TB infection as indicated by a positive ELISPOT test (greater than 17 sfc/million PBMC) in any ESAT6 peptide or CFP10 peptide poola
  3. Previous vaccination with candidate vaccine MVA85A or another recombinant MVA vaccine
  4. Clinically significant history of skin disorder, allergy, immunodeficiency (including human immunodeficiency virus [HIV]), cancer (except basal cell carcinoma [BCC] or carcinoma in situ [CIS]), cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse
  5. History of serious psychiatric condition
  6. Concurrent oral or systemic steroid medication or the use of other immunosuppressive agents
  7. History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study vaccine
  8. Any clinically significant abnormality of screening blood or urine tests
  9. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or HIV antibodies
  10. Female currently lactating, confirmed pregnancy or intention to become pregnant during study period
  11. Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the study vaccine for 30 days prior to dosing with the study vaccine, or planned use during the study period
  12. Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
  13. Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk or may influence the result of the study or may affect the volunteer's ability to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181856

Layout table for location information
United Kingdom
Centre of Clinical Vaccinology and Tropical Medicine (CCVTM) Churchill Hospital
Oxford, United Kingdom, OX3 7LJ
Sponsors and Collaborators
University of Oxford
Layout table for investigator information
Principal Investigator: Helen McShane University of Oxford
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT01181856    
Other Study ID Numbers: TB022
First Posted: August 13, 2010    Key Record Dates
Last Update Posted: March 28, 2011
Last Verified: March 2011
Keywords provided by University of Oxford:
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses